Cell
Volume 184, Issue 9, 29 April 2021, Pages 2384-2393.e12
Journal home page for Cell

Article
SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies

https://doi.org/10.1016/j.cell.2021.03.036Get rights and content
Under an Elsevier user license
open archive

Highlights

  • B.1.1.7, B.1.351, and P.1 do not show augmented host cell entry

  • Entry inhibitors under clinical evaluation block all variants

  • B.1.351 and P.1 can escape from therapeutic antibodies

  • B.1.351 and P.1 evade antibodies induced by infection and vaccination

Summary

The global spread of SARS-CoV-2/COVID-19 is devastating health systems and economies worldwide. Recombinant or vaccine-induced neutralizing antibodies are used to combat the COVID-19 pandemic. However, the recently emerged SARS-CoV-2 variants B.1.1.7 (UK), B.1.351 (South Africa), and P.1 (Brazil) harbor mutations in the viral spike (S) protein that may alter virus-host cell interactions and confer resistance to inhibitors and antibodies. Here, using pseudoparticles, we show that entry of all variants into human cells is susceptible to blockade by the entry inhibitors soluble ACE2, Camostat, EK-1, and EK-1-C4. In contrast, entry of the B.1.351 and P.1 variant was partially (Casirivimab) or fully (Bamlanivimab) resistant to antibodies used for COVID-19 treatment. Moreover, entry of these variants was less efficiently inhibited by plasma from convalescent COVID-19 patients and sera from BNT162b2-vaccinated individuals. These results suggest that SARS-CoV-2 may escape neutralizing antibody responses, which has important implications for efforts to contain the pandemic.

Keywords

SARS-CoV-2
COVID-19
variants
variants of concern
VOC
B.1.1.7
B.1.351
P.1
spike protein
host cell entry
antibodies
neutralization
escape

Cited by (0)

11

These authors contributed equally

12

Lead contact